NCT00673049_2A | R Documentation |
Kaplan-Meier digitized data from NCT00673049, figure 2A (PMID 25395283). A reported sample size of 583 for a primary endpoint of OS in lung cancer.
NCT00673049_2A
A data frame of 583 observations and 3 variables:
time | event time (in months) | |
event | OS event indicator (0 : no event, 1 : event) |
|
arm | treatment arms (control, figitumumab) | |
Scagliotti GV, Bondarenko I, Blackhall F, et al. Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer. Ann Oncol 2015; 26: 497–504.
summary(NCT00673049_2A)
kmplot(NCT00673049_2A)
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.